| |
| |
|
| Insider
Information: |
Svennilson Peter |
| Relationship: |
Director, 10% Owner |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
21,988,435 |
|
|
Indirect Shares
|
28,546,447 |
|
|
| Direct
Value |
$116,391,392 |
|
|
|
Indirect Value
|
$278,020,308 |
|
|
| Total
Shares |
50,534,882 |
|
|
| Total
Value |
$394,411,700 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
32
|
4
|
|
Stock
price went up :
|
32
|
1
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
32.0
|
32.0
|
| Percentage
Gain/Loss : |
 66.6%
|
 -51.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
Managing Partner, 10% ... |
2019-04-02 |
0 |
2017-10-27 |
6,642,942 |
Premium* |
|
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
2021-02-17 |
2,584,957 |
2021-02-17 |
3,645,681 |
Premium* |
|
|
Gritstone Oncology, Inc. |
GRTS |
Director, 10% Owner |
2018-10-02 |
0 |
2018-10-02 |
3,102,934 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
Managing Partner, 10% ... |
2020-08-28 |
17,988,843 |
2020-08-28 |
190,000 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director, 10% Owner |
|
0 |
2020-04-28 |
4,768,181 |
Premium* |
|
|
Revolution Medicines, Inc. |
RVMD |
Director |
2021-04-28 |
20,302 |
2021-04-28 |
3,145,258 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
|
Rapt Therapeutics, Inc. |
RAPT |
Director, 10% Owner |
2020-08-17 |
0 |
2020-09-22 |
5,630,497 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-06 |
4 |
AS |
$48.06 |
$1,898,441 |
I/I |
(39,500) |
1,868,205 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-05 |
4 |
AS |
$46.65 |
$849,817 |
I/I |
(18,215) |
1,889,154 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-07 |
4 |
AS |
$45.60 |
$1,274,783 |
I/I |
(27,953) |
1,853,380 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-08 |
4 |
AS |
$44.80 |
$2,071,204 |
I/I |
(46,228) |
1,828,862 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-09 |
4 |
AS |
$43.83 |
$1,082,541 |
I/I |
(24,701) |
1,815,761 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-26 |
4 |
AS |
$42.85 |
$2,270,174 |
I/I |
(52,984) |
1,787,660 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-27 |
4 |
AS |
$42.65 |
$994,922 |
I/I |
(23,326) |
1,775,289 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • – |
2021-04-28 |
4 |
AS |
$42.50 |
$4,250 |
I/I |
(100) |
1,775,236 |
0 |
% |
|
| CNST |
Constellation Pharmaceuti... |
10% Owner |
– – • |
2021-02-17 |
4 |
S |
$36.95 |
$369,503 |
I/I |
(10,000) |
99,155 |
0 |
% |
|
| RVMD |
Revolution Medicines, Inc... |
Director |
– • • |
2020-11-16 |
4 |
S |
$36.40 |
$73,788,478 |
I/I |
(2,027,156) |
2,429,180 |
0 |
% |
|
| RAPT |
Rapt Therapeutics, Inc. |
Director |
– • • |
2020-09-22 |
4 |
S |
$30.85 |
$18,756,800 |
I/I |
(608,000) |
3,835,679 |
0 |
% |
|
| CNST |
Constellation Pharmaceuti... |
Managing Partner |
– – • |
2020-03-20 |
4 |
B |
$23.15 |
$128,228 |
D/D |
5,539 |
6,051,376 |
2.45 |
% |
|
| RAPT |
Rapt Therapeutics, Inc. |
Director |
– • • |
2020-08-17 |
4 |
S |
$22.75 |
$12,254,379 |
I/I |
(538,654) |
4,443,679 |
0 |
% |
|
| CNST |
Constellation Pharmaceuti... |
Managing Partner |
– – • |
2020-03-19 |
4 |
B |
$22.38 |
$808,701 |
D/D |
36,135 |
6,045,837 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2020-02-26 |
4 |
B |
$18.00 |
$67,518 |
I/I |
3,751 |
16,469,480 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2020-03-05 |
4 |
B |
$18.00 |
$149,526 |
I/I |
8,307 |
16,612,351 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-08-25 |
4 |
B |
$18.00 |
$1,800 |
D/D |
100 |
1,700,442 |
2.37 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2020-03-03 |
4 |
B |
$17.99 |
$697,256 |
I/I |
38,758 |
16,594,058 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-08-21 |
4 |
B |
$17.97 |
$131,558 |
D/D |
7,321 |
1,689,318 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
Director |
– • • |
2020-03-04 |
4 |
B |
$17.96 |
$179,349 |
I/I |
9,986 |
16,604,044 |
2.25 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-08-24 |
4 |
B |
$17.96 |
$197,991 |
D/D |
11,024 |
1,700,342 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-24 |
4 |
B |
$17.93 |
$1,232,670 |
D/D |
68,749 |
1,609,013 |
2.45 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
